Medicare to review use of anemia drugs

03/15/2007 | NYTimes.com

Medicare officials plan to review the use of three anemia drugs in light of concerns about potentially harmful side effects. The review could determine whether Medicare continues to pay for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC